Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.34 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21685763 | 0.88 | NPC1 (0.39) | NPC1KMT2APIK3CBPPARGMAPT | |
| SCHEMBL3078966 | 0.82 | SMN1; SMN2 (0.40) | NPC1SMN1; SMN2TLR7PPARGMAPT | |
| SCHEMBL21684567 | 0.82 | DGAT1 (0.39) | NPC1TLR7PPARGMAPTALDH1A1 | |
| SCHEMBL24512710 | 0.82 | NPC1 (0.40) | NPC1KMT2APIK3CBMAPTPTGER4 | |
| SCHEMBL3192274 | 0.82 | CASR (0.39) | NPC1SMN1; SMN2MAPTMAP4K1ALDH1A1 | |
| SCHEMBL3070127 | 0.81 | SMN1; SMN2 (0.35) | NPC1SMN1; SMN2MAPTMAP4K1ALDH1A1 | |
| SCHEMBL21684336 | 0.77 | KDM4E (0.38) | NPC1SMN1; SMN2MEN1KMT2APIK3CB | |
| SCHEMBL29117063 | 0.76 | TLR8 (0.38) | NPC1SMN1; SMN2TLR7 | |
| SCHEMBL22717628 | 0.73 | ALDH1A1 (0.38) | NPC1SMN1; SMN2KMT2APIK3CBMAPT | |
| SCHEMBL21684566 | 0.73 | F11 (0.38) | NPC1PPARGMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842688-B2 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2010-11-30 | — | — | US | disclosed |
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20090012055-A1 | Organic compounds | HEROLD PETER | 2009-01-08 | — | — | US | disclosed |
| EP-1961752-A2 | Piperidine Compounds | Speedel Experimenta AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
| EP-1670760-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012055-A1 | Organic compounds | REN, ACE, ACE2 | NPC1 794/4885SMN1; SMN2 4291/4885MEN1 2817/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | NPC1 794/4885SMN1; SMN2 4291/4885MEN1 2817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.